A Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor in Patients With CD22 B-cell Malignancies
PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment
50
Participants
Timeline
Start Date
November 1, 2025
Primary Completion Date
April 1, 2027
Study Completion Date
January 1, 2028
Conditions
B Cell Malignancies
Interventions
OTHER
CD22 CAR-T cells
CD22 CAR-T cells
Trial Locations (1)
Unknown
Sheba Medical Center, Ramat Gan
All Listed Sponsors
lead
Sheba Medical Center
OTHER_GOV
NCT07135466 - A Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor in Patients With CD22 B-cell Malignancies | Biotech Hunter | Biotech Hunter